Literature DB >> 10392579

Progress in determining the causes and treatment of multiple sclerosis.

J H Noseworthy1.   

Abstract

The cause of multiple sclerosis remains unknown after more than a century of study. Unconfirmed work has once more indicated that a viral infection may be important in the aetiology of the disease, and there is considerable evidence for an important genetic influence on disease susceptibility. The clinical course is as variable as that of any disease in medicine. Studies using serial magnetic resonance imaging have helped to define the disease course and response to experimental therapies. Although the predominant pathological characteristic is myelin loss with preservation of axons, some studies recall classic descriptions that irreversible axonal destruction may occur, perhaps even in the early stages of the illness. There are now several, partially effective therapies for relapsing forms of multiple sclerosis and here I review progress in determining the timing and course of the illness and the steps that need to be taken to identify more effective treatments for this disease.

Entities:  

Mesh:

Year:  1999        PMID: 10392579     DOI: 10.1038/399a040

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  59 in total

Review 1.  Interferon in relapsing-remitting multiple sclerosis.

Authors:  G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis.

Authors:  S Sathornsumetee; D B McGavern; D R Ure; M Rodriguez
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

Review 4.  Immunotherapy of inflammatory demyelinating diseases of the central nervous system.

Authors:  J J Bright; S Sriram
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.

Authors:  Trudy Owens; Nikos Evangelou; David K Whynes
Journal:  Eur J Health Econ       Date:  2012-01-24

6.  Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T.

Authors:  Sumita Adhya; Glyn Johnson; Joseph Herbert; Hina Jaggi; James S Babb; Robert I Grossman; Matilde Inglese
Journal:  Neuroimage       Date:  2006-09-22       Impact factor: 6.556

7.  Pain, Fatigue, and Cognitive Symptoms Are Temporally Associated Within but Not Across Days in Multiple Sclerosis.

Authors:  Anna L Kratz; Susan L Murphy; Tiffany J Braley
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

8.  Ecological Momentary Assessment of Pain, Fatigue, Depressive, and Cognitive Symptoms Reveals Significant Daily Variability in Multiple Sclerosis.

Authors:  Anna L Kratz; Susan L Murphy; Tiffany J Braley
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

9.  Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus.

Authors:  Taeg S Kim; Stanley Perlman
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

10.  Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression.

Authors:  Anthony L Traboulsee; Cecily Q Bernales; Jay P Ross; Joshua D Lee; A Dessa Sadovnick; Carles Vilariño-Güell
Journal:  Neurogenetics       Date:  2014-04-26       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.